Hydroxyethyl starch versus saline for resuscitation of patients in intensive care: long-term outcomes and cost-effectiveness analysis of a cohort from CHEST

The Lancet Respiratory Medicine

Volumn 4, Issue 10, 2016, Pages 818-825

  Taylor, Colman ^a,b   Thompson, Kelly ^a   Finfer, Simon ^a,b   Higgins, Alisa ^c   Jan, Stephen ^a   Li, Qiang ^a   Liu, Bette ^d   Myburgh, John ^a,b,d  

^a GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Centre of Cardiovascular Research Education in Therapeutics School of Public Health and Preventive Medicine   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HETASTARCH; SODIUM CHLORIDE; CRYSTALLOID; HETASTARCH DERIVATIVE; ISOTONIC SOLUTION; PLASMA SUBSTITUTE;

ADULT; ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; FEMALE; FLUID RESUSCITATION; HOSPITAL COST; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; MORTALITY; MULTICENTER STUDY; NEW SOUTH WALES; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; AGED; COST BENEFIT ANALYSIS; ECONOMICS; INTENSIVE CARE; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; RESUSCITATION;

AGED; COHORT STUDIES; COST-BENEFIT ANALYSIS; CRITICAL CARE; FEMALE; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; ISOTONIC SOLUTIONS; MALE; MIDDLE AGED; NEW SOUTH WALES; PATIENT OUTCOME ASSESSMENT; PLASMA SUBSTITUTES; RESUSCITATION; SODIUM CHLORIDE;

EID: 84977529404     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30120-5     Document Type: Article

References (31)

1. 1 Myburgh, JA, Mythen, MG, Resuscitation fluids. N Engl J Med 369 (2013), 2462–2463.
2. 2 Myburgh, JA, Fluid resuscitation in acute medicine: what is the current situation?. J Intern Med 277 (2015), 58–68.
3. 3 Finfer, S, Liu, B, Taylor, C, et al., the SAFE TRIPS Investigators. Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units. Crit Care, 14, 2010, R185.
4. 4 Mutter, TC, Ruth, CA, Dart, AB, Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev, 7, 2013 CD007594.
5. 5 Perel, P, Roberts, I, Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev, 6, 2012 CD000567.
6. 6 Brunkhorst, FM, Engel, C, Bloos, F, et al., for the German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358 (2008), 125–139.
7. 7 Perner, A, Haase, N, Guttormsen, AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 367 (2012), 124–134.
8. 8 Myburgh, JA, Finfer, S, Bellomo, R, et al., for the CHEST investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367 (2012), 1901–1911.
9. 9 Australian Government, Department of Health and Ageing. Schedule of pharmaceutical benefits. http://www.pbs.gov.au/publication/schedule/2011/07/2011-07-01-general-schedule.pdf;jsessionid=1fkv0u772jyyyzgu178rvoyz/, July 31, 2011 (accessed Dec 8, 2015).
10. 10 NSW Government, Ministry of Health. Costs of care standards 2009/10. http://www0.health.nsw.gov.au/policies/gl/2011/pdf/GL2011_007.pdf, May 26, 2011 (accessed May 1, 2015).
11. 11 Gallagher, M, Cass, A, Bellomo, R, et al., for the POST-RENAL Study Investigators and the ANZICS Clinical Trials Group. Long-term survival and dialysis dependency following acute kidney injury in intensive care: extended follow-up of a randomized controlled trial. PLoS Med, 11, 2014, e1001601.
12. 12 The Crystalloid versus Hydroxyethyl Starch Trial (CHEST) Management Committee. The Crystalloid versus Hydroxyethyl Starch Trial: protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality. Intensive Care Med 37 (2011), 816–823.
13. 13 Myburgh, J, Li, Q, Heritier, S, Dan, A, Glass, P, Statistical analysis plan for the Crystalloid Versus Hydroxyethyl Starch Trial (CHEST). Crit Care Resusc 14 (2012), 44–52.
14. 14 EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 16 (1990), 199–208.
15. 15 Dolan, P, Gudex, C, Kind, P, Williams, A, A social tariff for EuroQol: results from a UK general population survey, 1995, The University of York, York.
16. 16 Viney, R, Norman, R, Brazier, J, et al. An Australian discrete choice experiment to value eq-5d health states. Health Econ 23 (2014), 729–742.
17. 17 Australian Government Department of Health. Round 14 (2009–10) National Public Cost Weight Tables—version 6.0× and version 5.2. http://www.health.gov.au/internet/main/publishing.nsf/Content/Round_14-cost-reports, Nov 9, 2012 (accessed Oct 7, 2015).
18. 18 Briggs, AH, Gray, AM, Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 3 (1999), 1–134.
19. 19 Bland, JM, Altman, DG, Statistics notes: bootstrap resampling methods. BMJ, 350, 2015, h2622.
20. 20 Shiroiwa, T, Sung, YK, Fukuda, T, Lang, HC, Bae, SC, Tsutani, K, International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?. Health Econ 19 (2010), 422–437.
21. 21 Higgins, AM, Harris, AH, Health economic methods: cost-minimization, cost-effectiveness, cost-utility, and cost-benefit evaluations. Crit Care Clin 28 (2012), 11–24.
22. 22 Australian Government Department of Health. The Pharmaceutical Benefits Scheme: public summary documents by product. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/public-summary-documents-by-product, April 18, 2016 (accessed April 9, 2016).
23. 23 Harris, GB, Mitchell, A, Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 19 (2001), 1103–1109.
24. 24 Knaus, WA, Draper, EA, Wagner, DP, Zimmerman, JE, APACHE II: a severity of disease classification system. Crit Care Med 13 (1985), 818–829.
25. 25 Kellum, JA, Bellomo, R, Ronco, C, The concept of acute kidney injury and the RIFLE criteria. Contrib Nephrol 156 (2007), 10–16.
26. 26 Perner, A, Haase, N, Winkel, P, et al. Long-term outcomes in patients with severe sepsis randomised to resuscitation with hydroxyethyl starch 130/0.42 or Ringer's acetate. Intensive Care Med 40 (2014), 927–934.
27. 27 Ramsey, SD, Willke, RJ, Glick, H, et al. Cost-effectiveness analysis alongside clinical trials, II: an ISPOR Good Research Practices Task Force report. Value Health 18 (2015), 161–172.
28. 28 Farrugia, A, Bansal, M, Balboni, S, Kimber, MC, Martin, GS, Cassar, J, Choice of fluids in severe septic patients: a cost-effectiveness analysis informed by recent clinical trials. Rev Recent Clin Trials 9 (2014), 21–30.
29. 29 Adhikari, NKJ, Fowler, RA, Bhagwanjee, S, Rubenfeld, GD, Critical care and the global burden of critical illness in adults. Lancet 376 (2010), 1339–1346.
30. 30 Wang, AY, Bellomo, R, Cass, A, et al. Health-related quality of life in survivors of acute kidney injury: The Prolonged Outcomes Study of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy study outcomes. Nephrology (Carlton) 20 (2015), 492–498.
31. 31 Skinner, EH, Warrillow, S, Denehy, L, Health-related quality of life in Australian survivors of critical illness. Crit Care Med 39 (2011), 1896–1905.